Managing Declined GFR on Medication

Initial Assessment and Management

The American Journal of Kidney Diseases recommends assessing whether the decline in GFR is an expected hemodynamic effect or true nephrotoxicity requiring intervention, and then systematically reviewing all nephrotoxic agents, temporarily discontinuing them during acute illness, and adjusting doses based on the new GFR level 1, 2
A 10-20% increase in serum creatinine after starting ACE inhibitors or ARBs represents an expected and beneficial hemodynamic effect, not acute kidney injury, according to the American Journal of Kidney Diseases 3
For RAAS antagonists, the American Journal of Kidney Diseases suggests assessing GFR and measuring serum potassium within 1 week of starting or following any dose escalation 1
More significant declines in GFR (>30%) or continued progressive decline warrant immediate medication review and possible discontinuation, as recommended by the American Journal of Kidney Diseases 1

The American Journal of Kidney Diseases recommends that NSAIDs are the most common reversible cause of GFR decline, and prolonged NSAID therapy is not recommended when GFR <60 mL/min/1.73m² and should be avoided entirely when GFR <30 mL/min/1.73m² 1, 4
The American Journal of Kidney Diseases suggests that metformin is safe when GFR ≥45 mL/min/1.73m², but review use when GFR drops below 45 mL/min/1.73m², and avoid when GFR <30 mL/min/1.73m² 1, 4
Aminoglycosides require dose reduction and/or increased dosing interval when GFR <60 mL/min/1.73m², and monitoring of serum levels (trough and peak) is necessary, as recommended by the American Journal of Kidney Diseases 1, 4

The American Journal of Kidney Diseases recommends avoiding nephrotoxic combinations, such as combining NSAIDs with RAAS blockers and diuretics, which dramatically increases acute kidney injury risk 3
Avoiding oral phosphate-containing bowel preparations when GFR <60 mL/min/1.73m² due to the risk of phosphate nephropathy is recommended by the American Journal of Kidney Diseases 1, 4
For radiocontrast procedures, using the lowest possible dose, avoiding high osmolar agents, ensuring adequate hydration with saline before/during/after the procedure, and discontinuing nephrotoxic agents temporarily is recommended by the American Journal of Kidney Diseases 1, 4

Measuring GFR within 1 week after starting or escalating RAAS antagonists is recommended by the American Journal of Kidney Diseases 1
Monitoring serum potassium and electrolytes concurrently with GFR assessments is necessary, as recommended by the American Journal of Kidney Diseases 1, 2
For aminoglycosides, monitoring serum trough and peak levels is necessary, as recommended by the American Journal of Kidney Diseases 1, 4